Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2001

View Archived Issues

Positive preliminary data obtained for frozen OrCel in Rx of venous leg ulcers

Chronogesic advances to phase III trials at Durect

CTD's orBec enters phase II for treatment of Crohn's disease

Aventis reviews progress over last nine months

Abgenix licenses rights to human antiproperdin monoclonal antibodies

Allergan and ExonHit to collaborate on new molecular targets

Enrollment commences in phase I/II Neoquin trial for early-stage bladder cancer

Vical receives HIV vaccine milestone payment

Icos starts human trials for PDE4 inhibitor IC-485

Positive phase IV results reported for Olux in mild to moderate body psoriasis

Icos acquires rights to resiniferatoxin for urological disorders

Oral pan-erbB tyrosine kinase inhibitor shows evidence of activity, good tolerance in phase I

Orally active taxane profiled at recent international cancer conference

Sepracor reviews third quarter progress

Optimal dose and schedule of administration determined for Apomine

Clinical evaluation of novel anticancer agent CT-2584 summarized at recent meeting

Trastuzumab-DM1 immunoconjugate heading for clinical testing next year

Novel cancer-related protein identified by Georgetown and NeoPharm

Second Oxxon pharmaccine enters clinical testing

Lead drug from Palatin exhibits preclinical efficacy in female sexual dysfunction

Chemokine IL-8 receptor antagonists claimed by GSK scientists

Japanese lab designs new compounds with selectivity for nicotinic alpha7 receptors

Prostaglandin derivatives with binding affinity for EP receptors and use thereof

Phenylpiperazine derivatives synthesized at SCRAS claimed for BPH, portal hypertension, cirrhosis

Novel series useful for hormone-dependent diseases and in hormone replacement therapy

Inhibitors of MEK potentially useful for proliferative disorders described in patent

Novel sigma-receptor ligands claimed for use in CNS, gastrointestinal and cardiovascular disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...